Appraising pharmaceutical products at different time points of their lifecycle open ups the possibility of reversals in estimates of economic value. A product that erstwhile was rated “not cost-effective” could later on become 'cost-effective'. This paper investigates, within a single...

Societal benefits of improving the efficiency of manufacturing biologics can be large given static impacts on product supply, availability and prices as well as dynamic impacts on future product R&D. This paper examines the static impacts of manufacturing process innovations using a dataset of...

Public health-sectors of most low- and middle-income countries (LMICs) run a central medical stores (CMS) supply chain model in their efforts to assure commodity security, defined as uninterrupted supply of health commodities whenever and wherever these commodities are needed. Concerns raised...

Health planners and program managers charged with the task of building or at least maintaining the health of populations within communities, districts, regions or countries have to find ways of assuring a steady (predictable) supply of health commodities for the production of needed healthcare...

Consumption of quality-assured medicines is expected to maintain or improve population health. Yet in a number of situations, what is realized is lower health benefits or magnified safety-risks. Recognizing the public-health implications of safety-risks or medication-related harm, and that harm...

The administration of (biologically-derived) drugs for various disease conditions involves consumption of resources that constitutes a direct monetary cost to healthcare payers and providers. An often ignored cost relates to a mismatch between patients' preferences and the mode of drug...

The administration of (biologically-derived) drugs for various disease conditions involves consumption of resources that constitutes a direct monetary cost to healthcare payers and providers. An often ignored cost relates to a mismatch between patients’ preferences and the mode of drug...

Objective: To value services that help organisations to manage performance concerns with doctors, dentists or pharmacists. Methods: Qualitative and quantitative methods. Qualitative analysis consists of: a literature review; interviews with support service providers and clinical professional...

Biologic drugs, as with all other medical technologies, are subject to a number of regulatory, marketing, reimbursement (financing) and other demand-restricting hurdles applied by healthcare payers. One example is the routine use of cost-effectiveness analyses or health technology assessments to...

Biologic drugs, as with all other medical technologies, are subject to a number of regulatory, marketing, reimbursement (financing) and other demand-restricting hurdles applied by healthcare payers. One example is the routine use of cost-effectiveness analyses or health technology assessments to...